Klinische Studien sind der Motor des medizinischen Fortschrittes. Wir möchten möglichst vielen Patientinnen und Patienten die Chance auf eine Studienteilnahme ermöglichen, um zukünftig die Therapien zugunsten besserer Heilungsraten und verbesserter Lebenqualität unserer Patienten optimieren zu können.
Aktuell können wir für viele Tumorerkrankungen Studien in unterschiedlichen klinischen Phasen (I-IV) anbieten. Neben dem Einsatz neuartiger Kombinationen der Bestrahlung mit innovativen Medikamenten prüfen wir auch technische Weiterentwicklungen zur präziseren und schonenderen Behandlung. In den Beratungsgesprächen mit unseren Patienten nehmen wir uns viel Zeit, um über die Möglichkeiten einer Studienteilnahme zu informieren.
Rekrutierende Studien
SNOXA | Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol
(NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected
First-line Glioblastoma Patients with Unmethylated MGMT Promoter. |
CureVac-GBM
(CV-GBLM-001) | A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of
CVGBM in Patients with Surgically Resected Glioblastoma (GBM) or Astrocytoma
with a Molecular Signature of Unmethylated Glioblastoma. |
Improve Codel (NOA18) | Improvement of functional outcome for patients with newly diagnosed
grade II or III glioma with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18
trial. |
EORTC1634 (NOA23) | Personalized risk-adapted therapy in post-pubertal patients with newly
diagnosed medulloblastoma (PersoMed-I). |
MecMeth (NOA24) | Phase I/II trial of meclofenamate/temozolomide therapy in relapsed
MGMT - Phase I/II trial of meclofenamate/temozolomide combination therapy in relapsed MGMT-methylated glioblastoma. |
MS202359_002 (XRay) | A randomized, double-blind, placebo-controlled, 2-arm Phase III study to
assess efficacy and safety of xevinapant and radiotherapy compared to placebo
and radiotherapy for demonstrating improvement of disease-free survival in
participants with resected squamous cell carcinoma of the head and neck, who
are at high risk for relapse and are ineligible for high-dose cisplatin. |
EORTC1420 | Phase III study assessing The “best of” radiotherapy compared to the
“best of” surgery (trans-oral surgery (TOS) in patients with T1-T2, N0
oropharyngeal carcinoma. |
OLIGOMA | Lokale Strahlentherapie von Metastasen beim oligometastasierten Mammakarzinom. |
ACO/ARO/AIO-18.1 | Preoperative oxaliplatin-based chemoradiotherapy
and consolidation chemotherapy
versus fluorouracil-based chemoradiotherapy for MRI-defined intermediate and
high-risk rectal cancer patients |
Studien in Kooperation
PATHOS | Full Title: A Phase II/III trial of risk-stratified, reduced intensity
adjuvant treatment in patients undergoing transoral surgery for Human
papillomavirus (HPV)-positive oropharyngeal cancer Short Title: Post-operative
adjuvant treatment for HPV-positive tumours (PATHOS) |
ADRISK | Postoperative adjuvant radio chemo therapy (aRCH) with Cisplatin (C)
versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck
squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within
the German interdisciplinary study group of German Cancer Society (IAG KHT);
Pembro-Adjuvant-highRisk |
RACE | Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with
Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal
Junction (GEJ) A randomized phase III joint study of the AIO, ARO and DGAV |
iEuroEwing | INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA (UCCL) |
20.09.2023
Kontakt
Gerne können Sie uns per E-Mail (nadja.talhi@uniklinikum-leipzig.de) oder Telefon (0341 - 97 18210 oder 0341- 97 18400) kontaktieren, wenn Sie Fragen zu klinischen Studien haben. Eine Übersichts unseres Teams finden Sie hier.
